Bioethics Experts vs Ordinary South Africans on the Governance of Human Genome Editing
On the issue of human genome editing, attitudes between bioethics scholars and the general public diverge.
Gene editing
-
Read more: Bioethics Experts vs Ordinary South Africans on the Governance of Human Genome Editing -
Read more: Responding to the Comeback of He Jiankui, ‘The CRISPR Baby Scientist’: Lessons from Criminal Justice Theory Responding to the Comeback of He Jiankui, ‘The CRISPR Baby Scientist’: Lessons from Criminal Justice Theory
By thinking carefully about what justice should entail, the scientific community will be better able to tailor their response to Dr. He.
-
Read more: The Not-So-Sacred Human Genome: What South Africans Think About Heritable Human Genome Editing The Not-So-Sacred Human Genome: What South Africans Think About Heritable Human Genome Editing
The participants overwhelmingly supported changing the human genome if this offers promise of a better life.
-
Read more: Establishing Standards for Gene Editing: Initial Steps from Private and Public Actors Establishing Standards for Gene Editing: Initial Steps from Private and Public Actors
By Phebe Hong Nine months have passed since the startling news broke in November 2018 that Chinese researcher He Jiankui had used CRISPR/Cas9 to genetically modify the embryos of twin girls. The controversial news spurred the scientific and regulatory community into action. In late August 2019, two influential organizations — one from the private sector…
-
Read more: Regulation of Human Genome Editing in the Dawn of the CRISPR Era Regulation of Human Genome Editing in the Dawn of the CRISPR Era
The more jurisdictions that adopt a cautionary approach to their own regulations for genome editing, the more likely it is that negative world-wide consequences can be mitigated.
-
Read more: Recharting the Course of Sickle Cell Disease – Who will Benefit? Recharting the Course of Sickle Cell Disease – Who will Benefit?
Ethical principles of health equity and justice must be examined as these new therapies are developed and progress to first-in-human clinical trials.
-
Read more: Of Risk and Gene Drives Of Risk and Gene Drives
It is possible that particular gene drives will kill us all. But academia’s emphasis on the risks of human, rather than environmental, genetic engineering mean their heads are in the right place.
-
Read more: Gene Editing and Intellectual Property: A Useful Mix? Gene Editing and Intellectual Property: A Useful Mix?
Join us March 8 for a talk that will cover the science of genome editing, including CRISPR, and in particular, the scientific advances made in the field since its principal discovery as an engineering tool in 2012.
-
Read more: The Luxturna Debate: Why Ethics Needs a Seat at the Drug Pricing Table The Luxturna Debate: Why Ethics Needs a Seat at the Drug Pricing Table
Jack Hogan can now ride his bike home at dusk after an afternoon of playing with his friends. Is that childhood rite-of-passage worth $850,000?
-
Read more: Opportunities and challenges for user-generated licensing models in gene-editing Opportunities and challenges for user-generated licensing models in gene-editing
By Timo Minssen, Esther van Zimmeren & Jakob Wested An earlier version of this contribution had been published in Life Science Intellectual Property Review (LSIPR). A voluntary pool or clearinghouse model may give rise to a robust commercial ecosystem for CRISPR and could include special provisions for royalty-free research use by academics. Hence, there may be a path through…